SEC Filing Analysis: MAIA Biotechnology, Inc. (MAIA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Director received a routine stock option grant of 32,012 shares at an exercise price of $1.18 pursuant to the company's equity incentive plan.
• Market Impact: Neutral; standard compensation grant representing negligible dilution.

Company Information

Field	Value
Company	MAIA Biotechnology, Inc.
Ticker Symbol	MAIA
CIK	0001878313
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Theagene Jean-Manasse
CIK	0001969857
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-09-30
Transaction Code	A (Award/Grant)
Security Type	Stock Options
Shares Involved	32,012
Price Per Share	$0.00 (Exercise Price: $1.18)
Total Value	$0.00
Shares Owned After	32,012 options
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.00
% of Market Cap ($70M)	0.00%
Shares Transacted	32,012
% of Shares Outstanding	0.05%
Post-Transaction Ownership	32,012 shares (0.05% diluted)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: Across MAIA's $70 million micro-cap valuation, this award represents standard board compensation.
• Dilution Impact: Minimal dilution risk at ~0.05% of the 60.80 million shares outstanding.
• Transaction Significance: Low significance as an equity grant without open-market capital outlay.

Market Impact Analysis

• Stock Impact Direction: Neutral
• Reasoning: Non-open market equity compensation grant.
• Volume & Sentiment: Negligible volume impact and neutral market sentiment expected.

Additional Context

• Vesting & Terms: Granted under the 2021 Equity Incentive Plan, fully vested on September 30, 2026, expiring on September 30, 2036.